Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Miriam Y, Kim"'
Autor:
Miriam Y. Kim, Reyka Jayasinghe, Jessica M. Devenport, Julie K. Ritchey, Michael P. Rettig, Julie O’Neal, Karl W. Staser, Krista M. Kennerly, Alun J. Carter, Feng Gao, Byung Ha Lee, Matthew L. Cooper, John F. DiPersio
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-17 (2022)
Chimeric antigen receptor T cells represent a breakthrough treatment in hematologic malignancies, but insufficient level of cytotoxicity and persistence of T cells might compromise success. Authors show here that a recombinant long acting form of int
Externí odkaz:
https://doaj.org/article/57d87d554b9b4960b607af4e9bf488c8
Autor:
Francesca Ferraro, Agata Gruszczynska, Marianna B. Ruzinova, Christopher A. Miller, Mary Elizabeth Percival, Geoffrey L. Uy, Iskra Pusic, Meagan A. Jacoby, Mathew J. Christopher, Miriam Y. Kim, Peter Westervelt, Amanda F. Cashen, Mark A. Schroeder, John F. DiPersio, Camille N. Abboud, Lukas D. Wartman, Feng Gao, Daniel C. Link, Timothy J. Ley, John S. Welch
Publikováno v:
Haematologica, Vol 107, Iss 7 (2022)
Externí odkaz:
https://doaj.org/article/a2116fd8e43648e69c98851780c8a622
Autor:
Miriam Y. Kim, Matthew L. Cooper, Miriam T. Jacobs, Julie K. Ritchey, Julia Hollaway, Todd A. Fehniger, John F. DiPersio
Publikováno v:
JCI Insight, Vol 6, Iss 16 (2021)
Targeting T cell malignancies with universal CD7-targeting chimeric antigen receptor T cells (UCART7) can lead to profound immune deficiency due to loss of normal T and NK cells. While a small population of endogenous CD7– T cells exists, these cel
Externí odkaz:
https://doaj.org/article/26744d5e00b8483a8c866070dcd5c761
Autor:
Julia Klermund, Saar Gill, Toni Cathomen, Aisha A. AlJanahi, Yifan Zhou, Miriam Y. Kim, Kyung-Rok Yu, Bradley Toms, So Gun Hong, David J. Young, Cicera R. Lazzarotto, Xing Fan, Shirley Chen, Stefan Cordes, Geoffroy Andrieux, Shengdar Q. Tsai, Tae-Hoon Shin, Yuesheng Li, Byung-Chul Lee, Ilker Tunc, Cynthia E. Dunbar, Isabel Jabara, Lauren L. Truitt
Publikováno v:
Mol Ther
The programmable nuclease technology CRISPR-Cas9 has revolutionized gene editing in the last decade. Due to the risk of off-target editing, accurate and sensitive methods for off-target characterization are crucial prior to applying CRISPR-Cas9 thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a270ea692de14a5bf2342f6b674eb73a
https://doi.org/10.1016/j.ymthe.2021.06.016
https://doi.org/10.1016/j.ymthe.2021.06.016
Autor:
Joseph C. Rimando, Ezhilarasi Chendamarai, Michael P. Rettig, Reyka Jayasinghe, Matthew J. Christopher, Julie K. Ritchey, Stephanie Christ, Miriam Y. Kim, Ezio Bonvini, John F. DiPersio
Publikováno v:
Blood.
Acute myeloid leukemia (AML) relapse is one of the most common and significant adverse events following allogeneic hematopoietic cell transplantation (HCT). Downregulation of major histocompatibility class II (MHC-II) surface expression on AML blasts
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa87b8d95017fae1b2a9751e017d046b
https://pubmed.ncbi.nlm.nih.gov/36563336
https://pubmed.ncbi.nlm.nih.gov/36563336
Autor:
Meagan A. Jacoby, John S. Welch, Peter Westervelt, Matthew Christopher, Geoffrey L. Uy, Ravi Vij, Keith E. Stockerl-Goldstein, Brad S. Kahl, Iskra Pusic, John F. DiPersio, Mark A. Schroeder, Miriam Y. Kim, Todd A. Fehniger, Armin Ghobadi, Christine J. Gu, Wade Anderson, Kathryn Vanderlaag, Kamran Ali, Camille Pataki, Markus D. Lacher
Publikováno v:
Cancer Research. 83:4342-4342
Introduction: Offering the optimal frontline treatment to a patient with acute myeloid leukemia (AML) requires trading off expected benefit and risk. Typical standard of care intensive induction chemotherapy (e.g., cytarabine plus idarubicin (7+3)) r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::718e7b65f31f563995f455dc9b959e1f
https://doi.org/10.1158/1538-7445.am2023-4342
https://doi.org/10.1158/1538-7445.am2023-4342
Autor:
Timothy Schappe, Pamela Wong, Marco L. Davila, Neha Mehta-Shah, Amanda F. Cashen, Wei Meng, John F. DiPersio, Matthew L. Cooper, Brad S. Kahl, Maximilian Schaettler, Jennifer Tran, Melissa M. Berrien-Elliott, Feng Gao, Lynne Marsala, Carly Neal, Nancy D. Marin, Miriam Y. Kim, Margery Gang, Nancy L. Bartlett, Todd A. Fehniger, Mark P. Foster
Publikováno v:
Blood
Natural killer (NK) cells are a promising cellular immunotherapy for cancer. Cytokine-induced memory-like (ML) NK cells differentiate after activation with interleukin-12 (IL-12), IL-15, and IL-18, exhibit potent antitumor responses, and safely induc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93066a933731b8effde2f62a36a2474d
https://doi.org/10.1182/blood.2020006619
https://doi.org/10.1182/blood.2020006619
Autor:
Francesca, Ferraro, Agata, Gruszczynska, Marianna B, Ruzinova, Christopher A, Miller, Mary Elizabeth, Percival, Geoffrey L, Uy, Iskra, Pusic, Meagan A, Jacoby, Mathew J, Christopher, Miriam Y, Kim, Peter, Westervelt, Amanda F, Cashen, Mark A, Schroeder, John F, DiPersio, Camille N, Abboud, Lukas D, Wartman, Feng, Gao, Daniel C, Link, Timothy J, Ley, John S, Welch
Publikováno v:
Haematologica. 107(7)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ecaac84a7efd5f0edac27c2d2fc93bc8
https://pubmed.ncbi.nlm.nih.gov/35236053
https://pubmed.ncbi.nlm.nih.gov/35236053
Autor:
Benjamin A. Garcia, Saar Gill, Dylan M. Marchione, Konrad Gabrusiewicz, Kimberly Veliz, Xueqing Maggie Lu, Nicholas R. Anderson, Olga Shestova, Miriam Y. Kim, Feng Shen, Stephen R. Wallace, Michael Klichinsky, Xinhe Shan, Carl H. June, Roddy S. O’Connor, Kristin Blouch, Maksim Shestov, Marco Ruella, Yumi Yashiro-Ohtani, Miroslaw Kozlowski, Martha Zeeman, Katherine D. Cummins, Maggie Schmierer, Andrew Best, Nicholas E. Petty, Saad S. Kenderian
Publikováno v:
Nat Biotechnol
Chimeric antigen receptor (CAR) T cell therapy has shown promise in hematologic malignancies, but its application to solid tumors has been challenging1–4. Given the unique effector functions of macrophages and their capacity to penetrate tumors5, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::895eb28dde195b326d70d18034d5ba3d
https://hdl.handle.net/11390/1242990
https://hdl.handle.net/11390/1242990
Autor:
Byung-Chul Lee, So Gun Hong, Yifan Zhou, Ilker Tunc, Toni Cathomen, Saar Gill, Tae-Hoon Shin, Stefan Cordes, Julia Klermund, Cicera R. Lazzarotto, Lauren L. Truitt, Kyung-Rok Yu, Cynthia E. Dunbar, Yuesheng Li, Shirley Chen, Shengdar Q. Tsai, Bradley Toms, David J. Young, Miriam Y. Kim, Aisha A. AlJanahi, Isabel Jabara
The programmable nuclease technology CRISPR/Cas9 has revolutionized gene editing in the last decade. Due to the risk of off-target editing, accurate and sensitive methods for off-target characterization are crucial prior to applying CRISPR/Cas9 thera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4fc5452cf5482c6bfb0c0a051aade4c9
https://doi.org/10.1101/2020.07.05.186858
https://doi.org/10.1101/2020.07.05.186858